Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study

Risk-adapted treatment in acute lymphoblastic leukemia (ALL) relies on genetic information and measurable residual disease (MRD) monitoring. In this proof of concept study, DNA from diagnostic bone marrow (BM) of six children with ALL, without stratifying genetics or central nervous system (CNS) inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Arthur, Cecilia, Rezayee, Fatemah, Mogensen, Nina, Saft, Leonie, Rosenquist, Richard, Nordenskjöld, Magnus, Harila-Saari, Arja, Tham, Emma, Barbany, Gisela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296121/
https://www.ncbi.nlm.nih.gov/pubmed/35865473
http://dx.doi.org/10.3389/fonc.2022.899325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296121/
https://www.ncbi.nlm.nih.gov/pubmed/35865473
http://dx.doi.org/10.3389/fonc.2022.899325

Ejemplares similares